Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K. Barta, Joseph A. Sparano, Xiaonan Xue et al.|Blood|2013Cited by 189
Eight Cycles of ABVD Versus Four Cycles of BEACOPP<sub>escalated</sub>Plus Four Cycles of BEACOPP<sub>baseline</sub>in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup TrialPatrice Carde, Nicolas Mounier, Matthias Karrasch et al.|Journal of Clinical Oncology|2016Cited by 121
High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation RegistryNicolas Mounier, Anna Sureda, Carmen Canals et al.|Transplantation and Cellular Therapy|2011Cited by 118
ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.Patrice Carde, Nicolas Mounier, Catherine Fortpied et al.|Journal of Clinical Oncology|2012Cited by 50
Central nervous system involvement in <scp>AIDS</scp>‐related lymphomasStefan K. Barta, Joseph A. Sparano, Jitesh Joshi et al.|British Journal of Haematology|2016Cited by 26